BioTech

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Ph

Source: globenewswire.com MacroGenics Inc. has announced positive results from SOPHIA, a Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. Margetuximab is...

GlaxoSmithKline will partner with Merck KGaA, Darmstadt, to co-develop and co-commercialize the cancer immunotherapy candidate M7824 (bintrafusp alfa), through a collaboration that could generate more than €3.7 billion ($4.2 billion) for German Merck.

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive op

Charles River and Toxys have entered into an agreement to offer access to ToxTracker® in North America.

FLIR Systems, Inc. (NASDAQ: FLIR) announced today that it has acquired Aeryon Labs Inc., a leading developer of high-performance unmanned aerial syste

DARMSTADT, Germany, January 24, 2019 /PRNewswire/ -- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editin

Pluristem Therapeutics Inc. (PSTI) announced the receipt of a joint grant awarded by the Israeli Ministry of Defense and the Israel Innovation Authority for the development of the company's PLX cells for the treatment of burn injuries.

Source: globenewswire.com Immunomedics Inc. has received a Complete Response Letter from the U.S. Food and Drug Administration (US FDA) for the Biologics License Application seeking...

The retailer is terminating its deal with its PBM, putting commercial and managed Medicaid beneficiaries out-of-network.